APMI and APMI-CP
Founding President: H. Hampel, MD, PhD, MSc
Scientific Director: S. Lista, PhD
Medical Director: A. Vergallo, MD
Structural Neuroimaging: E. Cavedo, PhD
Functional Neuroimaging: P.A. Chiesa, PhD
Data Science: P. Lemercier, MSc
The Precision Medicine strategy is assumed to facilitate a paradigm shift from the traditional “one-size-fits-all” approach in drug discovery towards biomarker-guided “tailored” therapies, i.e. targeted and timed interventions adapted to the biological profile of the individual patients: the right drug, for the right patients, at the right time.
In this context, the U.S. Precision Medicine Initiative (PMI) (https://obamawhitehouse.archives.gov/precision-medicine) and the U.S. “All of Us Research Program” (https://allofus.nih.gov/) – have been successfully developed.
During the last decade, large-scale exploratory blood-based biomarker studies indicate pathophysiological commonalities between Alzheimer’s Disease and several oncological / immunological diseases including genetic-epigenetic mechanisms, intracellular signaling, and protein expression profiles. Therefore, successful cross-fertilization between advanced medical research fields, including oncology and immunology, and neurology offers unique opportunities to open new therapeutic discovery and development perspectives for Alzheimer’s Disease.
In order to advance the development of the Precision Medicine paradigm in Alzheimer’s Disease, we have recently launched the Alzheimer Precision Medicine Initiative (APMI), a consortium conceptually linked to the U.S. “All of Us Research Program”.